The Impact of Comorbid Nasal Polyps on Real-World Mepolizumab Effectiveness in Patients with Severe Asthma: Results from the REALITI-A Study

Real‐world effectiveness of mepolizumab in severe asthma and chronic rhinosinusitis in the United States: Impact of comorbidity and sinus surgery

“…Because this study used real‐world data from a large claims database, the results are more likely to reflect typical patients in daily US clinical practice, in contrast to the more selective populations included in randomized controlled trials. These data complement previous post hoc analyses of clinical trials and observational studies that showed greater clinical benefits of mepolizumab for patients with asthma and upper airway disease such as CRS, compared with patients with severe asthma alone, including improvements in asthma exacerbations, lung function, CRS symptoms, and health‐related quality of life 18,19,26–28 …”

“…These data complement previous post hoc analyses of clinical trials and observational studies that showed greater clinical benefits of mepolizumab for patients with asthma and upper airway disease such as CRS, compared with patients with severe asthma alone, including improvements in asthma exacerbations, lung function, CRS symptoms, and health-related quality of life. 18,19,[26][27][28] Several reasons may explain why mepolizumab appeared to have the most benefit for patients with severe asthma plus comorbid CRS and sinus surgery in this study. Comorbidities such as CRSwNP are often associated with more severe asthma and IL-5-driven T2 inflammation, characterized by eosinophilia.…”